|1.||Crohn Disease (Crohn's Disease)
|1.||Rutgeerts, Paul: 63 articles (12/2015 - 02/2002)|
|2.||Danese, Silvio: 45 articles (12/2015 - 01/2003)|
|3.||Gisbert, Javier P: 44 articles (10/2015 - 03/2002)|
|4.||Sandborn, William J: 43 articles (12/2015 - 01/2002)|
|5.||Vermeire, Séverine: 40 articles (12/2015 - 09/2004)|
|6.||Neurath, Markus F: 38 articles (12/2015 - 07/2003)|
|7.||Van Assche, Gert: 38 articles (12/2015 - 07/2004)|
|8.||Peyrin-Biroulet, Laurent: 38 articles (10/2015 - 01/2007)|
|9.||Rogler, Gerhard: 34 articles (04/2015 - 11/2003)|
|10.||Pallone, Francesco: 33 articles (01/2016 - 08/2003)|
|1.||Azathioprine (Imuran)FDA LinkGeneric
06/01/2013 - "Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. "
01/01/2016 - "Azathioprine [AZA] is recommended for maintenance of steroid-free remission in inflammatory bowel disease IBD. "
01/01/2014 - "Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. "
03/01/2011 - "Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients."
01/01/2011 - "The immunosuppressant azathioprine (AZA) is widely used in the treatment of inflammatory bowel disease (IBD) for both inducing and maintaining remission. "
|2.||6-Mercaptopurine (Mercaptopurine)FDA LinkGeneric
04/01/2003 - "6-Mercaptopurine (6-MP) has proven efficacy in the therapy of inflammatory bowel disease. "
10/01/1989 - "Improved treatment of individuals with severe inflammatory bowel disease with potent immunosuppressive medications such as 6-mercaptopurine has been previously demonstrated. "
11/01/2010 - "6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). "
11/01/1995 - "[Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease]."
10/15/1989 - "Our data, showing a low incidence of toxicity in 396 patients, coupled with the previously demonstrated efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease, indicate that the drug is a reasonable alternative in the management of patients with intractable inflammatory bowel disease."
|3.||infliximab (Remicade)FDA Link
10/01/2015 - "Clinical proof of efficacy for biosimilars for infliximab has been achieved in rheumatoid diseases because activity indices are more stable than in inflammatory bowel diseases and require extrapolation. "
09/01/2015 - "Infliximab (IFX) is effective in the treatment of inflammatory bowel diseases (IBD). "
05/01/2015 - "A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease."
11/01/2014 - "Infliximab (IFX) is effective in the treatment of inflammatory bowel disease; however, the effect is often not durable. "
12/01/2013 - "[Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect]."
|4.||Mesalamine (Mesalazine)FDA LinkGeneric
10/01/1994 - "These studies strongly suggest that mesalazine microgranules are effective for idiopathic inflammatory bowel disease."
10/01/2014 - "Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. "
04/01/2013 - "5-aminosalicylic acid (5-ASA) is widely used for the treatment of inflammatory bowel disease (IBD). "
10/01/2012 - "Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease. "
05/18/2009 - "Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease. "
|5.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/01/2015 - "Since the introduction of anti-tumor necrosis factor (TNF) therapy as treatment of inflammatory bowel disease (IBD), care of pediatric and adult patients with IBD has significantly improved. "
04/01/2014 - "Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy."
06/18/2005 - "The introduction of immunosuppressors and anti-TNF alpha agents for chronic inflammatory bowel diseases constitutes a major advance in the management of their severe forms, but nevertheless raises the issues of whether their use should be systematic or depend on the severity of the disease. "
03/01/2015 - "Biological agents for inflammatory bowel diseases (IBD) targeting tumor necrosis factor (TNF) have changed the way to treat IBD refractory to standard medications and allowed us to reach new therapeutic goals such as mucosal healing and deep remission. "
05/07/2013 - "Tumor necrosis factor-α inhibitors (anti-TNFs) are effective in the treatment of inflammatory bowel disease (IBD) recalcitrant to conventional medical therapy. "
|6.||Sulfasalazine (Azulfidine)FDA LinkGeneric
08/01/1992 - "Sulfasalazine is an important therapeutic agent in the management of chronic inflammatory bowel disease (CIBD). "
08/01/2001 - "5-ASA, sulfasalazine and 6-MP, while beneficial in inflammatory bowel disease, do not directly control MAdCAM-1, and are beneficial through inhibition of other inflammatory processes."
10/01/1991 - "Sulphasalazine and 5-ASA, at concentrations of 10(-5)-10(-3) M significantly inhibit lipid peroxidation, suggesting an antioxidant action that may explain the efficacy of these drugs in treating inflammatory bowel disease. "
12/01/1981 - "On the contrary, sulphasalazine resulted in a reduced response which was significantly greater for the group with inflammatory bowel disease than the control group (P less than 0.05). "
01/01/2001 - "Since its synthesis in the 1930s and subsequent introduction, sulfasalazine has been an effective treatment for inflammatory bowel disease. "
|7.||Methotrexate (Mexate)FDA LinkGeneric
04/01/2015 - "Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease."
06/01/1997 - "If methotrexate is proven to be effective in inflammatory bowel disease, it should be administered orally."
05/01/2012 - "Methotrexate is an effective treatment for inflammatory bowel disease (IBD). "
09/01/2004 - "Methotrexate is reasonably effective in clinical practice as a steroid sparing agent in inflammatory bowel disease. "
05/01/2002 - "A literature search was conducted to examine the safety and effectiveness of low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. "
|8.||Adrenal Cortex Hormones (Corticosteroids)IBA
10/01/2003 - "In initial independent clinical studies, these two new models have produced striking clinical efficacy, safety, and a marked reduction in the dose of corticosteroids used to induce remission of active inflammatory bowel disease. "
07/01/2008 - "Fifteen patients with severe or very severe inflammatory bowel disease on corticosteroids but not responding to medication received 12 sessions of "gut-focused hypnotherapy" and were followed up for a mean duration of 5.4 years with disease severity being graded as remission, mild, moderate, severe, or very severe. "
09/01/2008 - "Corticosteroids are the mainstay of medical therapies to induce remission in acute episodes of inflammatory bowel disease (IBD). "
04/01/2003 - "Corticosteroids are effective against diarrhoea associated with inflammatory bowel disease, but their effectiveness in treating inflammatory diarrhoea of C difficile has not been reported. "
03/01/2002 - "Although newer therapeutic agents are being developed for the treatment of inflammatory bowel disease, aminosalicylates and corticosteroids remain the mainstay of treatment for UC (Tables 2-5). "
01/01/2009 - "Furthermore, through downregulation of proinflammatory cytokines, Enprocal appears to be beneficial in reducing the effects of chronic gut inflammatory diseases such as inflammatory bowel disease (IBD). "
06/01/2005 - "Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells."
04/01/2015 - "The identification of new cytokines, as well as the changing of the pathogenesis paradigms in inflammatory bowel diseases has been done on animal tests and clinical studies. "
01/01/2013 - "To study biological (cell and anticytokine) therapy-induced changes in the levels of proinflammatory cytokines in patients with inflammatory bowel diseases (IBD). "
12/01/2012 - "The aim of this study was to explore the expression of cytokines by Th17 cells and their mechanisms of action in a mouse model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced inflammatory bowel disease (IBD). "
|10.||Tacrolimus (Prograf)FDA LinkGeneric
09/01/2010 - "Tacrolimus is a potent immunomodulator that is effective in the treatment of inflammatory bowel disease (IBD). "
02/01/2009 - "Tacrolimus is a potent immunomodulator that is effective in the systemic treatment of inflammatory bowel diseases (IBD). "
10/01/1998 - "Tacrolimus induced rapid remission in steroid resistant inflammatory bowel disease in the majority of cases. "
07/01/2004 - "Recently, tacrolimus was shown to be effective in mitigating inflammatory bowel disease (IBD). "
05/15/2003 - "Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease."
12/01/2009 - "Conventional therapies remain the mainstay of treatment for most patients with inflammatory bowel disease (IBD), with only a minority of patients requiring biologic therapies. "
04/01/2013 - "Introduction of biologic therapy in clinical practice represented significant progress in the treatment of inflammatory bowel diseases (IBD) because of its proven efficacy and due to the fact that biologics are the first drugs used in the treatment of IBD that can change the natural course of this diseases. "
01/01/2008 - "We seek evidence and provide direction for clinicians about the optimal use of biologic therapy in order to enable steroid free remission in inflammatory bowel disease. "
02/01/2015 - "Biologic therapy has been shown to be effective in achieving and maintaining remission in the treatment of inflammatory bowel disease (IBD). "
04/01/2011 - "Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis."
|2.||Blood Component Removal (Apheresis)
12/01/2011 - "Leukocytes are thought to play an important role in the pathogenesis of inflammatory bowel diseases; granulocyte-monocyte adsorptive (GMA) apheresis, an extracorporeal technique aimed at removing activated circulating leukocytes from the blood, may represent a safe and effective therapeutic tool in these patients. "
10/01/2008 - "We assessed whether selective granulocyte and monocyte/macrophage adsorption apheresis maintained clinical remission in asymptomatic inflammatory bowel disease (IBD) patients at significant risk of clinical relapse. "
01/01/2012 - "Adsorptive granulocyte apheresis (GCAP) is a new treatment for inflammatory bowel disease. "
01/01/2012 - "The present reviews analyzes the data on the safety and efficacy of apheresis in those patients with inflammatory bowel diseases who could benefit from this technique."
04/01/2008 - "Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study."
05/01/2007 - "Oral gene therapy has significant promise for treatment of local diseases such as inflammatory bowel disease and for systemic absorption of the expressed protein therapeutics. "
01/06/2005 - "This review focuses on specific, recent advances made in understanding cellular pathways and mechanisms that regulate dynamic processes of these barriers and examines the feasibility of drug delivery strategies focusing on macromolecular therapeutics potentially useful in the treatment of inflammatory bowel disease (IBD)."
01/01/1999 - "Recent advances in inflammatory bowel disease therapeutics have led to improved formulations of existing treatments and new indications for established drugs. "
01/21/2008 - "The incidence of pediatric inflammatory bowel disease (IBD) is rising and recent advances in diagnostics and therapeutics have improved the care provided to these children. "
12/01/2015 - "Colonic drug delivery is intended not only for local treatment in inflammatory bowel disease (IBD) but also for systemic delivery of therapeutics. "
|4.||Enteral Nutrition (Feeding, Tube)
08/01/2011 - "Exclusive enteral nutrition (EEN) is an effective method of treatment in achieving remission in inflammatory bowel disease (IBD); however, its mechanism of action is still poorly understood. "
01/01/2006 - "[Clinical efficacy of enteral nutrition in inflammatory bowel diseases]."
10/01/1998 - "Children and adolescents attending the inflammatory bowel disease clinic at our hospital underwent treatment either with enteral nutrition (Study A) or intestinal resection (Study B). "
01/01/2015 - "3.18 Enteral nutrition for paediatric inflammatory bowel disease."
01/01/2015 - "Enteral nutrition (EN) is considered to be of great importance in patients with inflammatory bowel disease (IBD) and nutritional problems. "
10/01/2003 - "Clinical data suggest that leukocytapheresis might be an effective adjunct to therapy for inflammatory bowel disease to promote remission, taper conventional drug dosage, and potentially reduce the number of patients who require colectomy. "
05/01/2015 - "The Pubmed and Embase databases were searched using the terms "inflammatory bowel disease," "children," "adolescents," "laparoscopic," and "colectomy." The review identified 10 appropriate studies. "
02/01/2012 - "The purpose of this study was to report the results of alternative specimen extraction techniques after laparoscopic emergency colectomy in patients with inflammatory bowel disease (IBD). "
08/23/2010 - "Studies have shown that laparoscopic colectomy (LC) for inflammatory bowel disease (IBD) is just as safe as open colectomy. "
01/01/2005 - "One hundred one patients underwent subtotal colectomy for inflammatory bowel disease during the study period. "